A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study
| Autor: | Cortes, Jorge, Baccarani, Michele *, Guilhot, François, Druker, Brian J., Branford, Susan *, Kim, Dong-Wook, Pane, Fabrizio *, Rudoltz, Marc, Yu, Richard *, Collins, LaTonya *, Krahnke, Tillmann *, Radich, Jerald P. *, Hughes, Timothy P * |
|---|---|
| Zdroj: | In Blood 16 November 2008 112(11):335-335 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|